Cite
Predicting performance of the HAS-BLED and ORBIT bleeding risk scores in patients with atrial fibrillation treated with Rivaroxaban: Observations from the prospective EMIR Registry
MLA
Esteve-Pastor, María A., et al. “Predicting Performance of the HAS-BLED and ORBIT Bleeding Risk Scores in Patients with Atrial Fibrillation Treated with Rivaroxaban: Observations from the Prospective EMIR Registry.” European Heart Journal - Cardiovasular Pharmacotherapy, vol. 9, no. 1, Jan. 2023, pp. 38–46. EBSCOhost, https://doi.org/10.1093/ehjcvp/pvac060.
APA
Esteve-Pastor, M. A., Rivera-Caravaca, J. M., Roldán, V., Sanmartin Fernández, M., Arribas, F., Masjuan, J., Barrios, V., Cosin-Sales, J., Freixa-Pamias, R., Recalde, E., Pérez-Cabeza, A. I., Manuel Vázquez Rodríguez, J., Ràfols Priu, C., Anguita Sánchez, M., Lip, G. Y. H., & Marin, F. (2023). Predicting performance of the HAS-BLED and ORBIT bleeding risk scores in patients with atrial fibrillation treated with Rivaroxaban: Observations from the prospective EMIR Registry. European Heart Journal - Cardiovasular Pharmacotherapy, 9(1), 38–46. https://doi.org/10.1093/ehjcvp/pvac060
Chicago
Esteve-Pastor, María A, José M Rivera-Caravaca, Vanessa Roldán, Marcelo Sanmartin Fernández, Fernando Arribas, Jaime Masjuan, Vivencio Barrios, et al. 2023. “Predicting Performance of the HAS-BLED and ORBIT Bleeding Risk Scores in Patients with Atrial Fibrillation Treated with Rivaroxaban: Observations from the Prospective EMIR Registry.” European Heart Journal - Cardiovasular Pharmacotherapy 9 (1): 38–46. doi:10.1093/ehjcvp/pvac060.